Published March 21, 2025 | Version v.1

MASCC antiemetic consensus recommendations: resource-limited settings

  • 1. Department of Supportive Oncology and Palliative Care, Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia
  • 2. Department of Medical Oncology, Cancer Institute (WIA)The institution will open in a new tab, Chennai, Adyar, India
  • 3. Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
  • 4. Genolier Cancer Center, Genolier, Switzerland
  • 5. Department of Pharmacy, Gifu University HospitalThe institution will open in a new tab, Gifu, Japan
  • 6. The Medical Oncology Centre of Rosebank, Johannesburg, South Africa
  • 7. Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, United States

Description

Abstract

Purpose: Prevention of chemotherapy-induced nausea and vomiting (CINV) remains an essential supportive care need for patients receiving cancer treatment. Due to inadequate access to antiemetics in many countries, guideline-recommended CINV prophylaxis is not always possible. Our goal was to formulate antiemetic recommendations for resource-limited settings and define alternative antiemetic regimens for the CINV prophylaxis after highly (HEC) and moderately emetic chemotherapy (MEC), when NK1-receptor antagonists are not accessible.

Methods: The recommendations based on the MASCC/ESMO 2023 Guideline Update were considered as the best option. The stratification based on a meta-analysis published by Filetti et al. (2023) was used in order to select and rank NK1-receptor antagonist-free regimens by their probability of achieving complete response. Alternative NK1-receptor antagonist-free regimens based on olanzapine are proposed, ranked by their efficacy as "better" and "good" options when "best" regimens recommended by the MASCC/ESMO 2023 Guideline Update were not available or affordable.

Results: For the prevention of acute CINV, in patients receiving HEC (HEC-cisplatin and AC-HEC) with no access to an NK1-receptor antagonist, a 3-drug regimen including single doses of a 5-HT3-receptor antagonist, dexamethasone, and olanzapine given before chemotherapy is recommended as an alternative option. Olanzapine and dexamethasone are recommended days 2-4 after chemotherapy. The O10PD regimen (10 mg olanzapine, palonosetron, and dexamethasone) is suggested as the alternative regimen in the category "better." Other 5-HT3-receptor antagonists (ondansetron, granisetron) may be used if palonosetron is not affordable (category "good"). No guideline is possible for the alternative regimens to prevent acute CINV following MEC because of limited (carboplatin, AUC ≥ 5) or unavailable data (oxaliplatin chemotherapy in women aged < 50 years). Limited data are also available on the management of CINV following trastuzumab-deruxtecan.

Conclusion: The most effective prevention of CINV recommended by the MASCC/ESMO 2023 Guideline Update must be given when available and affordable. These recommendations were developed to facilitate decision on which regimen to use when the best MASCC/ESMO 2023 recommended regimen is not accessible because NK1-receptor antagonists are either not available or not affordable.

Other (English)

The most effective prevention of CINV recommended by the MASCC/ESMO 2023 Guideline Update must be given when available and affordable. These recommendations were developed to facilitate decision on which regimen to use when the best MASCC/ESMO 2023 recommended regimen is not accessible because NK1-receptor antagonists are either not available or not affordable.

Files

Restricted

The record is publicly accessible, but files are restricted. Log in to check if you have access.

Additional details

Additional titles

Alternative title
MASCC/ESMO 2023 GUIDELINE

Dates

Accepted
2025-01-26
Issued
2025-02-12

Software

Repository URL
https://zenodo.org/uploads/15064885
Development Status
Active